Bio-Techne Reports Fiscal 2026 Q4 Results Highlighting Growth and Strategic Acquisition

Bio-Techne Reports Fiscal 2026 Q4 Results

Bio-Techne Corporation (NASDAQ: TECH) has recently shared its financial results for the fourth quarter ending on June 30, 2026, marking an exciting close to the fiscal year. The company experienced organic revenue growth while also finalizing a strategic acquisition that promises to enhance its capabilities in the life sciences sector.

Financial Highlights

In the fourth quarter, Bio-Techne saw an organic revenue increase of 3%, amounting to $321.2 million. Comparatively, the full year’s figures indicated that overall revenues remained steady at $1.2 billion. Notably, the company reported earnings per share (EPS) of $0.35, recovering significantly from an EPS of $(0.11) during the same quarter last year. Adjusted EPS stood at $0.52, marginally down from $0.53 year-over-year. Over the full fiscal year, GAAP EPS rose to $1.16 from $0.46 in the prior year, demonstrating a solid financial turnaround.

Acquisition News

One of the key highlights of this quarter was the announcement of Bio-Techne's acquisition by Merck KGaA, a prominent German life sciences company. The deal is set at $73 per share, translating to an enterprise value of approximately $11.3 billion. This acquisition is anticipated to provide enhanced growth opportunities and a broader product portfolio for Bio-Techne’s customers and employees, as noted by the company's President and CEO, Kim Kelderman.

Segment Performance

Protein Sciences Segment

Bio-Techne’s Protein Sciences segment reported fourth-quarter sales of $231.2 million, which is a 2% increase from the $226.5 million recorded in the same quarter last year. Organic revenue within this segment achieved a modest growth of 1%. Despite these positive outcomes, the operating margin saw a slip to 42.0%, down from 43.6% the previous year, attributed to unfavorable volume and product mix.

For the full year, sales in the Protein Sciences segment were approximately $874.6 million, reflecting a slight rise of 1% from the prior year's $870.2 million.

Diagnostics and Spatial Biology Segment

Conversely, the Diagnostics and Spatial Biology segment maintained steady performance with fourth-quarter revenues that remained almost unchanged at $90.1 million, which is an increase of 8% in organic revenue despite a challenging market environment. The operational margin improved to 11.2%, a significant recovery from the previous year’s figure, bolstered by divestitures and growth initiatives.

In total, this segment generated $336.4 million for the full year, down from $346.3 million in fiscal 2025, demonstrating some volatility influenced by market dynamics.

Looking Forward

The management at Bio-Techne remains optimistic about the future, highlighting the value of their innovative solutions across biopharma, research, and diagnostic workflows. With ongoing integration planning with Merck KGaA, the company is poised to capitalize on increased market opportunities.

As Bio-Techne transitions into the next fiscal year, stakeholders are encouraged to keep a close watch on the company’s strategic expansions and operational enhancements.

Conclusion

Bio-Techne’s fourth-quarter fiscal results illustrate a blend of financial resilience and strategic maneuvering within the competitive life sciences landscape. The acquisition by Merck KGaA stands as a testament to the company's potential to grow and innovate in the years to come, presenting an appealing perspective for investors and industry observers alike.